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ABSTRACT
Introduction: The number of atrial fibrillation (AF) patients requiring thrombo-prophylaxis with oral
anticoagulation is greatly increasing. The introduction of non-vitamin K oral anticoagulants (NOACs) in
addition to standard therapy with dose-adjusted warfarin has increased the therapeutic options for AF
patients. Despite a generally better safety profile of the NOACs, the risk of major bleedings still persists,
and the management of serious bleeding is a clinical challenge.
Areas covered: In the current review, risk of major bleeding in patients taking NOACs and general
approaches to manage bleeding depending on severity, with a particular focus on specific reversal
agents, are discussed.
Expert commentary: Due to short half-life of NOACs compared to warfarin, discontinuation of drug,
mechanical compression, and volume substitution are considered to be sufficient measures in most of
bleeding cases. In case of life-threatening bleeding or urgent surgery, hemostasis can be achieved with
non-specific reversal agents (prothrombin complex concentrates) in patients treated with factor Xa
inhibitor until specific antidotes (andexanet α and ciraparantag) will receive approval. Thus far, idar-
ucizumab has been the only reversal agent approved for dabigatran.
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1. Introduction
Atrial fibrillation (AF) is the most common sustained arrhyth-
mia, and it confers increased risk of stroke and systemic
embolism when one or more additional stroke risk factors
are present [1,2]. The CHA2DS2-VASc score includes a cluster
of clinical risk factors associated with increased risk of throm-
boembolism, such as congestive heart failure, hypertension,
older age, diabetes mellitus, history of stroke or systemic
embolism, vascular disease, and female sex [3]. This score is
recommended by guidelines as the preferred decision-making
tool to identify patients requiring oral anticoagulation (OAC);
the use of CHA2DS2-VASc over CHADS2 score significantly
improved stroke risk stratification in AF [4] by identifying
truly low-risk patients (rate of thromboembolic events < 1%/
year) who do not need antithrombotic therapy [5,6].
Stroke prevention is pivotal component of AF management
with OAC being the only effective treatment [5–7]. While OAC
with warfarin is still a valid option for AF patients when quality
of anticoagulant control is good (i.e. time in therapeutic range
>70%) [8], many limitations of therapy with warfarin were
acknowledged. Indeed, clinical challenges for warfarin therapy
are represented by its narrow therapeutic range, variability of
anticoagulant effect over time, requirement of regular labora-
tory monitoring, numerous drug interactions, slow onset, and
prolonged half-life [7,9]. As result, a significant proportion of
AF patients with indication to receive OAC are not adequately
treated or not treated at all [10].
The fixed-dose non-vitamin K oral anticoagulants (NOACs)
were developed to overcome these issues and to improve
adherence to OAC. Thus far, the NOACs included a direct
thrombin inhibitor dabigatran etexilate and factor Xa (FXa)
inhibitors, namely, rivaroxaban, apixaban, and edoxaban
[9,11]. The safety and efficacy of each of the NOACs were
compared to warfarin in large phase 3 prospective rando-
mized clinical trials [12–15]. All the NOACs showed to be at
least as effective as warfarin for stroke prevention, along with
a better safety profile [12–15]. Thus, a significant reduction in
the rate of intracranial hemorrhage (ICH) was found for all
NOACs compared to warfarin (Table 1). Despite this favorable
profile of NOACs, unavailability of specific reversal agents to
manage life-threatening bleeding or to proceed without
delays with emergency surgery has been raised as a clinical
issue [9,11]. Other indications for treatment with NOACs are
represented by acute [17] and chronic venous thromboembo-
lism [18], where NOACs showed broadly similar effectiveness
compared to warfarin, with lower bleeding events [19–21] as
well as prophylaxis of venous thromboembolism in adult
patients hospitalized for an acute medical illness who are at
risk for thromboembolic complications [22].
Indications for the NOACs can be further expanded after
results of ongoing trials addressing OAC in peripheral artery
disease, heart failure, and secondary prevention of recurrent
strokes in patients with ischemic stroke of undetermined
source will become available [23].
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The aim of the current review is to provide a summary of
current knowledge on (1) assessment of risk of major bleeding
in patients taking NOACs, (2) management of bleeding with a
particular focus on use of specific reversal agents, and (3) the
resumption of OAC after a major bleeding.
2. Bleeding rates and risk stratification in AF
patients taking NOACs
Unsurprisingly, bleeding risk is significantly increased by
antithrombotic therapy [7,24]. Thus, the rate of bleeding is
significantly higher in patients receiving OAC compared to
the general population, ranging from 1.3% to 7.2% per year
according to different studies [25]. ICH represents the most
important life-threatening complication during OAC treat-
ment; warfarin-associated ICH is 7- to 10-fold higher than
spontaneous ICH, occurring in about 1% of patients on OAC
[26], and being associated with about 50% risk of death [27].
As mentioned before, all the NOACs were found to be at
least non-inferior or even superior to warfarin, and major
bleeding was the primary safety outcome in all registration
studies; of note, the ROCKET-AF trial evaluated also the inci-
dence of clinically relevant nonmajor bleeding. Rates of
hemorrhagic events reported in clinical trials are shown in
Table 1.
In patients treated with NOACs, a dramatic reduction in the
rate of ICH compared to warfarin was observed [28]. In parti-
cular, the severity of ICH was lower in terms of hematoma
volume, expansion, functional outcomes, and survival, as evi-
denced from cohort of patients treated with rivaroxaban [29].
Conversely, gastrointestinal bleeding was more common in AF
patients treated with rivaroxaban or high-dose dabigatran and
edoxaban [30].
Major hemorrhages developing at a background of antic-
oagulation with the NOACs are likely to have better outcomes.
For example, in patients from the ARISTOTLE cohort, mortality
within 30 days after a major bleeding episode was reduced by
50% in apixaban-treated patients than in those receiving war-
farin, and bleeds required shorter hospitalization, less medical
or surgical intervention, blood transfusion, or change in antith-
rombotic therapy [31]. The same trend was observed in
patients anticoagulated with dabigatran [32].
All results on safety favoring the NOACs were obtained in
the absence of specific reversal agents. Nonetheless, concerns
on development of the NOAC-related hemorrhage resulted in
off-label overuse of reduced doses of the NOACs [33,34].
Overall, a favorable efficacy-safety profile [30,35] together
with other advantages of the NOACs over warfarin [9,11] has
resulted in the update of clinical guidelines with NOACs
recommended as a first-choice therapy in OAC-naïve patients
as well as switching to NOAC may be considered in patients
who have labile international normalized ratio despite good
adherence [5]. Patients which were selected for OAC with
vitamin K antagonists in daily practice represent ‘selected’
population of patients with lower comorbidity, high quality
of anticoagulant control, and low stroke rates. However, this
did not result in lower risk of major bleeding and bleeding
outcomes were poor [36]. Of note, therapy persistence on the
NOACs is significantly higher than on warfarin [37,38].
Real-world data further reaffirmed the safety and efficacy of
the NOACs observed in the randomized trials [20,21,28,39–42].
However, high bleeding risk is not a reason to give up OAC
with the purpose of stroke prevention [5]. The evidence, which
supports initiation of OAC for prevention of stroke/systemic
embolism in the presence of one or more additional CHA2DS2-
VASc stroke risk factors, is based on positive net clinical ben-
efit of antithrombotic therapy against potential harm of ser-
ious bleeding [43,44]. On the contrary, patients with higher
bleeding risk often have also higher stroke risk, given stroke
and bleeding risk factors overlap, hence, OAC will be even
more beneficial [45,46].
Hence, bleeding risk has to be assessed at baseline and
during patient follow-up. Many bleeding risk scores have
been proposed so far to predict bleeding complications in AF
patients [25]. However, most of them only have modest pre-
dictive value for major bleeding, and some are difficult to apply
in daily clinical practice. The HAS-BLED score has been shown to
have significantly better predictive ability for major bleedings
than other proposed risk scores in the AF population [47–49].
This score incorporates bleeding risk factors such as uncon-
trolled hypertension, abnormal liver and/or renal function,
stroke history, bleeding history or predisposition, labile inter-
national normalized ratio control, elderly or frail condition, and
concomitant antiplatelet/anti-inflammatory drugs and/or alco-
hol use [50]. Thus, the HAS-BLED score includes modifiable risk
factors, which can be managed over time to reduce bleeding
risk [50]. Hence, treatment of elevated blood pressure, monitor-
ing of kidney function, discontinuation of unnecessary antipla-
telet agents, limitation in the use of nonsteroidal anti-
inflammatory drugs, and reduction of alcohol intake are all
factors that may favorably affect bleeding risk [1,2,51].
Thus, the HAS-BLED score is a simple and practical tool for
bleeding risk stratification in AF. Despite it was recently
tested also in non-AF populations, such as in patients on
no antithrombotic therapy, bridging therapy, and in patients
undergoing percutaneous coronary intervention [3,51], the
score needs further validation in these clinical settings.
Moreover, most of bleeding risk scores were developed and
tested in cohorts of patients treated with warfarin, so their
predictive ability in AF patients treated with NOAC is less
certain.
3. Management of bleeding in patients taking NOACs
More rapid onset and offset of action of the NOACs with
predictable pharmacokinetics and anticoagulant effect
(Table 2) make standard hemostatic measures such as
mechanical compression, surgical hemostasis, fluid replace-
ment, sufficient to cope with most of non-life-threatening
bleeding. An algorithm for the management of bleeding
according to its severity is reported in Figure 1. The same
applies for elective or urgent surgery, where postponement
of at least one half-life of the NOAC deems to be sufficient to
reduce risk of hemorrhagic complications [9,52].
In serious life-threatening bleeding or for hemorrhages
requiring emergency surgery procedure to be stopped, rever-
sal agents may play an important role in addition to hemody-
namic support and volume replacement (Figure 1). Also in this
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setting, information about last intake of NOAC should be
obtained to guide decision-making. Thus far, a specific reversal
agent, namely idarucizumab, is available only for dabigatran.
Specific antidotes for FXa inhibitors are currently under inves-
tigation (andexanet α and ciraparantag).
Conventional coagulation parameters are affected by
the NOAC and may provide some information about drug
activity (Table 2), but there is significant variability among
different assays, and a relation with risk of bleeding has
not been clearly established [9,52,53]. On the other hand,
quantitative assays require specific calibration for each
drug and may not be universally available. Performing
coagulation tests is time-consuming and may cause delays
especially in the management of life-threatening bleed-
ing [5,52].
4. Nonspecific reversal agents for NOACs
While waiting for firm data on efficacy and safety for specific
reversal agents for FXa inhibitors, prothrombin complex con-
centrates (PCCs) represent a reasonable alternative for antic-
oagulation reversal in serious bleeding, emergency surgery,
and more in general in situations, where a rapid reversal of
anticoagulation is needed. PCCs are highly effective for war-
farin reversal [54], as they are composed of vitamin
K-dependent coagulation factors (factors II, VII, IX, and X) and
are available as 3- or 4-factor PCC formulation, depending on
low or high level of factor VII, respectively [55]. There are non-
activated and activated (aPCC, factor VII predominantly in
active form) 4-factor PCCs, which also include some amount
of heparin, proteins C and S (non-activated 4-factor PCC) or
protein C (4-factor aPCC) to reduce thrombogenicity of these
compounds [55]. Common pitfalls to use PCC for OAC reversal
is their prothrombotic activity resulting in low but significant
increase in rate of thromboembolic complications, particularly
with 4-factor PCCs [56]. A recent systematic review reported a
Table 2. Pharmacological characteristics, laboratory measurement, and reversal strategies for the NOACs administered for stroke prevention in non-valvular AF.
Dabigatran Rivaroxaban Apixaban Edoxaban
Mechanism of action Direct thrombin inhibitor (free or
bound), reversible
Factor Xa inhibitor (free or bound),
reversible
Factor Xa inhibitor (free
or bound), reversible
Factor Xa inhibitor (free
or bound), reversible
Bioavailability, % 6.5 80 60 62
Tmax, hour 1–3 2.5–4 1–3 1–2
T1/2, hour 12–17 5–9 in younger pts; 11–13 in elderly pts 8–15 10–14
Renal excretion 80 35 27 50
Drug transporter P-gp P-gp, BCRP P-gp, BCRP P-gp
Drug–drug interactions Potent P-gp inhibitors and inducers Potent CYP3A4 and P-gp inhibitors Potent CYP3A4 and P-gp
inhibitors
Potent P-gp inhibitors
and inducers
Coagulation
measurement
Normal TT, aPTT exlude therapeutic
level of drug
Chromogenic anti-FXa assay is
preferred
Chromogenic anti-FXa
assay is preferred
Chromogenic anti-FXa
assay is preferred
dTT > 200 ng/ml Dose-dependent PT prolongation
(confirms presence of drug)
Changes in PT, aPTT, INR
are
Concentration-
dependent
ECT, ECA > 3 × ULN aPTT, INR are highly variable (do not
use)
highly variable (do not
use)
prolongation of PT,
aPTT
aPTT > 2 × ULN at trough drug
concentration indicate high bleeding
risk
PT, INR (do not use)
Reversal agents Idarucizumab Andexanet α Andexanet α Andexanet α
Ciraparantag Ciraparantag Ciraparantag
(experimental) (experimental) (experimental)
Nonspecific reversal agents PCC PCC PCC PCC
recombinant FVIIa recombinant FVIIa recombinant FVIIa recombinant FVIIa
tranexamic acid tranexamic acid tranexamic acid tranexamic acid
hemodialysis
aPTT: activated partial thromboplastin test; BCRP: breast cancer resistance protein; CYP: cytochrome P450 isozymes; dTT: diluted thrombin test; ECA: ecarin
chromogenic assay; ECT: ecarin clotting time; F: factor; INR: international normalized ratio; PCC: prothrombin complex concentrates; P-gp: permeability
glycoprotein; PT: prothrombin time; pts: patients; Tmax: time to maximum plasma concentration; TT: thrombin time; T1/2β: terminal half-life.
Figure 1. Decision pathway for management of bleeding or emergency surgery
in patients treated with NOAC.
CrCL, creatinine clearance; HAS-BLED, uncontrolled hypertension, abnormal liver and/or renal
function, stroke history, bleeding history or predisposition, labile international normalized ratio,
elderly or frailty, drugs concomitantly and/or alcohol abuse; Hb, hemoglobin; Ht, hematocrit;
NOAC, non-vitamin K oral anticoagulant; PCC, prothrombin complex concentrates; Pt, platelet
count; rVIIa, recombinant factor VIIa.
* This should be accompanied by hemodynamic support, plasma transfusion when signs of
coagulopathy appear, use of oral charcoal if the time since last intake of NOAC is expected to be
less than 2 h, hemodialysis for dabigatran.
† Specific reversal with andexanet α will be preferred to PCCs as soon as it will get approval of
regulatory agencies.
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rate of thromboembolic events of 2.5% in patients treated
with non-activated 4-factor PCC [57].
Another agent that is sometimes used for ICH is recombi-
nant factor VIIa (rFVIIa); however, its use for the treatment of ICH
is off-label, and no firm data on its efficacy and safety have been
provided so far [58]. Thus, even if rFVIIa use was shown to
significantly decrease relative hematoma expansion at all
doses, it was associated with an increased rate of arterial throm-
boembolism when given at medium- and high-doses [58].
The use of PCC or rFVIIa for reversal of the NOACs is off-
label. Current evidence for this is sparse, largely derived from
animal models and in vitro studies using surrogate endpoints
(e.g. volume of blood loss, normalization of coagulation tests,
thrombin generation) and providing mixed results [52,55].
In rat tail bleeding model, administration of six different
coagulation factor concentrates reduced dabigatran-induced
bleeding; however, none of the concentrates tested in the
study produced a consistent change in the coagulation assays
[59]. Moreover, thrombin generation in vitro was restored, but
this was observed only with lower baseline dabigatran con-
centrations [59]. In a porcine polytrauma model, blood loss in
dabigatran-anticoagulated pigs was significantly reduced by
aPCC [60]. In another study, a reduced blood loss by PCC in
murine coagulopathy induced by warfarin was reported, but
neither PCC (in combination with rVIIa or without it) nor aPCC
were able to prevent dabigatran-induced blood loss [61].
For rivaroxaban, rFVIIa and aPCC were more effective than
PCC in vitro in reversing prolongations of prothrombin time
and thrombin generation in plasma, and in thromboelastome-
try in whole blood from healthy subjects [62].
In a rabbit model of bleeding, administration of rFVIIa and
PCC partially improved laboratory parameters, but did not
reverse rivaroxaban-induced bleeding [63]. In 35 healthy
volunteers treated for 4 days with rivaroxaban 20 mg bid,
both 3- and 4-factor PCCs were able to partially reverse the
anticoagulant effect of rivaroxaban [64]. Two experimental
studies using mice models investigated the effect of PCC on
NOACs-induced ICH [65,66]; they reported that PCC therapy
was able to prevent intracerebral hematoma expansion for
both rivaroxaban and dabigatran-related ICH [65,66].
The only clinical trial that addressed use of nonspecific
reversal agents for the NOACs in human was the phase 1
study on edoxaban reversal with 4-factor PCC in healthy indi-
viduals, undergoing punch biopsies. Effects of edoxaban on
bleeding duration and endogenous thrombin potential were
completely reversed with dose of 50 IU/kg while changes in
prothrombin time and bleeding volume were partially
reversed [67].
Despite limited evidence, PCC are recommended to treat
severe/life-threating bleeding in patients treated with dabiga-
tran or FXa inhibitors, at a loading dose of 50 U/kg, followed by
an additional of 25 U/kg if clinically needed [5,9,68]. However, it
should be pointed out that within clinical trials and in real-
world cohorts the need for using pro-hemostatic nonspecific
reversal agents was very low [69–71]. There is no evidence of
additional efficacy of aPCC over PCC, then choice between
these two is determined by their availability, experience of the
treatment center, and inclusion in protocols. Activated PCC can
be considered before PCC if readily available [9].
5. Specific reversal agents for NOACs
5.1. Idarucizumab
Idarucizumab is a humanized monoclonal antibody Fab (frag-
ment antigen binding) produced from the IgG1 isotype mole-
cule with a molecular weight of 47,776 Da that was developed
to reverse specifically anticoagulant activity by dabigatran
[72]. The ability of idarucizumab to reverse rapidly effect of
dabigatran is determined by its very high affinity, which is
approximately 350-fold higher than that of dabigatran to
thrombin (binding affinity 2 pmol/l and 700 pmol/l, respec-
tively). Binding of idarucizumab to dabigatran is mediated via
hydrophobic interactions, H-bonds, and a salt bridge. It is
capable of binding both unbound dabigatran in plasma and
thrombin-bound fraction as well as active glucuronide meta-
bolites of dabigatran with 1:1 stoichiometry [72].
Structure of idarucizumab resembles structure of thrombin,
but idarucizumab does not bind to thrombin substrates (e.g.
coagulation factors V, VIII, XIII, and fibrinogen) and therefore
has no impact on coagulation out of dabigatran reversal, that
is, activation of coagulation factors, conversion of fibrinogen
to fibrin, or platelet activation [72]. Neither the levels of the
thrombosis markers (e.g. D-dimer, and prothrombin fragment
1 + 2) nor endogenous thrombin formation within 72 h after
the end of infusion of idarucizumab were increased compared
to placebo [73].
Furthermore, idarucizumab to dabigatran binding is char-
acterized with a rapid on rate (forward binding) and very slow
off rate (backward unbinding), making the interaction of two
substances almost irreversible with only minimal escape of
dabigatran from complex [72]. Thus, after infusion of idaruci-
zumab peak plasma concentration is achieved within 5 min,
while half-life is approximately 45 min. Such pharmacokinetic
properties allow a reversal of dabigatran activity within few
minutes from administration [74].
Table 3 provides overview of preclinical and clinical studies
addressed reversal of dabigatran with idarucizumab. In vitro
and ex vivo studies demonstrated that idarucizumab promptly
restores dabigatran-prolonged coagulation parameters to
baseline values, and studies in healthy volunteers and patients
with life-threatening bleeding or requiring emergency surgery
or invasive procedures show that it completely reverses the
anticoagulant effects of dabigatran within minutes in the
majority of patients. In the porcine model of trauma, adminis-
tration of idarucizumab 120 mg/kg was characterized by lower
blood loss and higher survival [82]. In the phase 3 RE-VERSE
AD study (Figure 2), reappearance of levels of dabigatran
above 20 ng/ml, a threshold below which impairment of
hemostasis is unlikely, was observed in 23% of patients usually
after 12 h, but only in 1.6% of patients the second dose of
idarucizumab was given because of recurrent or continued
bleeding or requirement for the second urgent procedure [83].
Based on this, the currently approved idarucizumab dose is
5 g to be administered intravenously as two consecutive 2.5 g
(50 ml) infusions in 5–10 min in duration each with no greater
than 15 min interval between infusions [84]; the second dose
may be potentially effective in controlling bleeding caused by
redistribution of unbound dabigatran. Also, lower dose of
idarucizumab (i.e. 2 g) was shown to be sufficient to bind
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dabigatran equivalent to mean peak steady-state concentra-
tions in healthy individuals treated with dabigatran 220 mg
bid (approximately 155 ng/ml) [75]. Dabigatran should be
restarted after administration of idarucizumab as soon as a
safe hemostatic condition has been achieved and thrombotic
risk outweighs the bleeding one. Thus, the rate of thrombotic
events was 4.8% and 6.8% at 30 and 90 days, respectively, in
patients with bleeding, and it was broadly similar in patients
undergoing surgery (5.0% and 4.6%, respectively). However,
comorbidity is more likely to have impact on outcomes rather
than reversal therapy [83].
5.2. Andexanet α
Andexanet α is a specific reversal agent for FXa inhibitors, both
direct (rivaroxaban, apixaban, edoxaban) and non-direct (low-
molecular-weight heparins and fondaparinux). Andexanet α is
recombinant FXa derivative with a molecular weight of approxi-
mately 39 kDa. It was developed as matured, functional form
with no need to be activated via intrinsic or extrinsic coagulation
pathways and causes rapid sequestration of the FXa inhibitors in
a 1:1 molar ratio followed by rapid recovery of FXa activity [85].
Factor Xa is an essential component of prothrombinase com-
plex, converting prothrombin to thrombin. The molecule of FXa
was modified to ensure catalytical inactivity of andexanet α. This
was achieved via substitution of serine residue by alanine residue
in active site of molecule [85]. The second fundamental difference
of the andexanet α from the native FXa is its inability to form
prothrombinase complex because of lacking membrane-binding
γ-carboxyglutamic acid domain [85]. These modifications allow
andexanet α to be non-reactive in terms of physiologic coagula-
tion activation via FXa -dependent mechanisms as well as not to
evince prothrombogenic properties. At the same time, affinity of
andexanet α to bind FXa inhibitors, direct or antithrombin III-
dependent, remains high (subnanomolar), and binding in circula-
tion also results in redistribution of anticoagulant from the extra-
vascular to the intravascular compartment. For example, six-fold
increase in rivaroxaban plasma concentration was observed after
andexanet α administration, but concentration of free, nonpro-
tein bound rivaroxaban remained very low [85,86].
In Table 4, preclinical and clinical studies on reversal effect
of andexanet α are summarized. Andexanet α led to recovery
of abnormal anti- FXa activity in vitro, corrected coagulation
tests, decreased volume of blood loss in animal bleeding
models. Effectiveness to rapidly reverse FXa inhibitors in
dose-dependent manner was observed in phase 2 studies
(Table 4), which lead to conduct phase 3 trials such as ‘A
Study in Older Subject to Evaluate the Safety and Ability of
Andexanet Alfa to Reverse the Anticoagulation Effect of
Rivaroxaban’ (NCT02220725) and ‘A Study in Older Subjects
to Evaluate the Safety and Ability of Andexanet Alfa to Reverse
the Anticoagulation Effect of Apixaban’ (NCT02207725) [93].
Andexanet α consistently reversed anticoagulant effect of
rivaroxaban and apixaban with anti-FXa activity reduction by
at least 80% in all studied patients. Also, thrombin generation,
blood clotting times affected by FXa inhibitors were restored,
along with a decrease in concentration of free unbound apix-
aban and rivaroxaban in plasma to very low level [93].
Following the ANNEXA-A and ANNEXA-R studies, the phase
3 multicenter, prospective, single-arm, open-label study
ANNEXA-4 (NCT02329327) was started, addressing reversal of
FXa inhibitors in anticoagulated patients who developed acute
major bleeding and given andexanet α within 18 h (Table 4).
Thus far, the trial is ongoing, and preliminary results have
Resumption of antithrombotic therapy (90-day follow-up)
73% at mean 13 days after idarucizumab
23% by 72 hrs of which 10% dabigatran
90% at mean 3.5 days after idarucizumab
67% by 72 hrs of which 26% dabigatran
30-day / 90-day clinical outcomes
Mortality 13.5% / 18.8%
Thrombotic events 4.6% / 6.3% 
Mortality 12.6% / 18.9%
Thrombotic events 5% / 7.4%
Idarucizumab 5 g (2.5 g + 2.5 g) intravenously within 15 min.
Onset of action 1-2  min.    T1/2 biphasic (initial 47 min., terminal 10.3 hrs) 
Reversal (assessed with dTT/ECT) within 4 hrs in 100% pts (immediate, maintained 24 hrs)
independent of age, sex, kidney function or dabigatran concentration at baseline.
Single 5 g dose sufficient in 98% pts
2.5 hrs until the bleeding had stopped 1.6 hrs required to initiate procedure93% normal hemostasis during procedure
503 dabigatran-treated patients 
62% 110 mg bid, 30% 150 mg bid 
95% AF pts, aged 78 yrs, CrCl 53 ml/min, 16 hrs from last dose, 92% elevated dTT/ECT at baseline
Uncontrolled or life-threatening bleeding 
(33% ICH, 46% GI, 26% traumatic, 17% other, 3% 
intramuscular, 3% retroperitoneal, 2% pericardial, 
2% intraarticular, etc.)
Emergency surgery or procedure
(24% peritoneal infection/ hernia, 20% 
fracture/septic arthritis, 18% pacemaker/aneurism 
repair, 8% craniotomy, 7% cholecystitis/cholangitis, 
7% chest trauma, 5% acute renal failure, etc.)  
Figure 2. Summary of the RE-VERSE AD study.
AF, atrial fibrillation; CrCl, creatinine clearance; dTT, diluted thrombin time; ECT, ecarin clotting time; GI, gastrointestinal; ICH, intracranial hemorrhage; T1/2, half-life
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been published on 67 patients (the study aims to enroll 350
patients) [94]. Key exclusion criteria of the study were the
scheduling of surgery within less than 12 h after presentation
(apart from a minimally invasive surgery); ICH with severe
coma (less than 7 according to Glasgow Coma Scale) or an
estimated intracerebral hematoma volume of more than
60 ml; expected survival of less than 1 month; the occurrence
of a major thrombotic event within 2 weeks before enroll-
ment; or receipt of one of the following agents within 7 days
before screening: vitamin K antagonist, dabigatran, PCC, or
whole blood or plasma.
Interestingly, 30% of enrolled patients did not qualify for
efficacy group based on their baseline level of anti-FXa activity
below 75 ng/ml, that is, high probability of good or excellent
hemostasis without specific reversal of anticoagulation. This
highlights again relatively rapid clearance of the NOACs, how-
ever, whether low levels of NOAC found in these patients were
due to a longer time since the last dose intake (i.e. one missed
dose) or to other reasons, such as concomitant intake of other
drugs reducing bioavailability, was not specified [94].
Gastrointestinal and ICHs represented the most frequent
reason for inclusion. Anti-FXa activity was effectively reversed
in all patients and 79% of patients achieved excellent or good
hemostasis at 12 h after infusion [94]. While no thrombotic
events occurred in the ANNEXA-A and ANNEXA-R studies, 18%
of patients in the ANNEXA-4 developed one ischemic complica-
tions including myocardial infarction, stroke, pulmonary embo-
lism, or deep vein thrombosis [94]. The fact that most of these
events occurred out of 3 days after andexanet α administration
supports their primary relation to background risk rather than
hypothetical procoagulant effect of reversal agent.
Some details, which might be helpful for interpretation of
these preliminary ANNEXA-4 results are lacking; for example,
exact time between onset of hemorrhage, start of andexanet α,
and complete hemostasis; drugs used concomitantly, enhan-
cing anticoagulant effect (e.g. antiplatelets, nonsteroidal anti-
inflammatory drugs, or inhibitors of intestinal P-glycoprotein);
general supportive measures (e.g. specific drug products).
These data suggest the need of more robust evidence on the
safety of andexanet. While trials comparing andexanet α with
current standard of care are not feasible, accumulation of evi-
dence and experience from real-world practices after andexa-
net α approval will be needed.
5.3. Ciraparantag
Ciraparantag (di-arginine piperazine; formerly known as aripa-
zine or PER977) is a small molecular weight (512 Da) thermally
stable, water-soluble, cationic synthetic molecule that is cap-
able of binding to unfractionated heparin, low-molecular-
weight heparin, fondaparinux, and all the NOACs [95].
Ciraparantag directly and specifically binds NOACs and hepar-
ins via non-covalent hydrogen bonding reversing their antic-
oagulant properties [95]. For example, there are four sites on
dabigatran to disallow from inhibiting factor IIa. Ciraparantag
showed no procoagulant properties and is not able to bind to
any human plasma coagulation factors or albumin [95]. No
interaction between ciraparantag with lisinopril, propafenone,
digoxin, hydrachlorothiazide, clopidogrel was shown, and
there was no evidence of immunogenicity of ciraparantag [95].
In the preclinical studies, ciraparantag was consistently
effective for reversal of the NOACs both in models of external
(rat tail transection) and internal bleeding (rat or rabbit liver
laceration models), as assessed via reduction of blood loss
(Table 5). Nonclinical safety assessment revealed no observa-
ble adverse effect during 2 weeks of intravenous exposure in
rats and dogs with dose up to 20 mg/kg/day. Consequently,
19.4 mg/day dose was selected for the ciraparantag in human
study [102]. In the phase 1 double-blind, placebo-controlled
study (Effects of a Double-Blind, Single Dose of PER977
Administered Alone, and Following a Single Dose of
Edoxaban, NCT01826266), pharmacokinetic and pharmacody-
namic effects of escalating, single intravenous doses of cira-
parantag to reverse anticoagulation achieved with edoxaban
60 mg in healthy individuals were studied. Ciraparantag at
dose 100–300 mg administered as single intravenous injection
3 h after last edoxaban intake, restored prolonged whole
blood clotting time (WBCT) in 10 min to within 10% above
the WBCT baseline value. The reversal effect persisted up to
24 h [100,101].
Of note, dynamic changes in WBCT induced by edoxaban
followed by ciraparantag administration were paralleled by
changes in the clot structure. Fibrin fibers in the clot as
assessed with scanning electron microscopy were reduced in
diameter from approximately 250 to 125 nm after edoxaban
and then fully recovered within half an hour after ciraparantag
dose [100,101]. There were significant changes neither in
D-dimer, prothrombin fragment 1.2, tissue factor pathway
inhibitor nor WBCT supportive of no prothrombotic effect of
ciraparantag [100,101]. Ciraparantag also blocked anticoagu-
lant effect of enoxaparin 1.5 mg/kg as efficiently as that of
edoxaban in the phase 1/2 study (Pharmacokinetics and
Pharmacodynamic of Single, Escalating Doses of PER977
Following Enoxaparin, NCT02206100) [103,104].
Results of two phase 2 studies are expected. The study of
PER977 administered to subjects with steady state edoxaban
dosing and re-anticoagulation with edoxaban (NCT02207257)
aimed to assess resumption of anticoagulation in 50 patients in
whom edoxaban was reversed by ciraparantag, and to establish
the dose of ciraparantag to block edoxaban effect for up to 21 h
with a randomized, sequential group, single-blind design [105].
Another study will address efficacy and safety of ciraparantag
for reversal of rivaroxaban (NCT03172910) [106].
6. Resumption of OAC after bleeding
Bleeding complications of OAC therapy represent major rea-
son for discontinuation of therapy with eventual increase in
risk of stroke, adverse cardiovascular events, and mortality
[107]. There is limited evidence when to resume OAC after
bleeding, particularly life-threatening, such as ICH. In one
retrospective cohort study from Germany, OAC resumption
in ICH survivors led to significantly lower rate of ischemic
complications, but rate of ICH recurrence remained
unchanged [108]. Specifically, incidence of cerebral infarctions
was 3.9 versus 12.7 per 100 person-years in patients who
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restarted OAC compared to those who did not, respectively,
translated into reduced mortality (8.3% vs. 30.7%) [108].
Consistent results were derived in the analysis of outcomes
of AF patients with incident OAC-related ICH from the Danish
nationwide registries showed lower rate of ischemic stroke or
systemic embolism and all-cause mortality in patients treated
with OAC compared to those non-anticoagulated (13.6 vs. 17.3
per 100 person-years) with no difference in recurrent ICH
between groups [109]. Thus, current guidelines advocate
opportunity to initiate or resume OAC after ICH within four
to eight weeks based on informed judgment and accounting
for patients’ values and preferences [5,110]. There is also
uncertainty about optimal timing of OAC resumption after
gastrointestinal bleeding [111]. In one study, more than half
of patients restarted OAC after vitamin K-associated bleeding
within median of 1 week. In these patients, reduced risk of
thromboembolism (HR 0.19) and death (HR 0.61) were found,
but an increased rate of recurrent gastrointestinal bleeding
was also observed (HR 2.5) [112]. Optimal timing of OAC
resumption appeared to be within 3–6 weeks after bleeding
[112–114], but should be cautiously extrapolated to NOACs
given potentially higher risk of gastrointestinal bleeding com-
pared to well-controlled warfarin.
7. Conclusions
Stroke and systemic embolism prevention with OAC has to be
balanced with bleeding risk. The introduction of four NOACs
with advantageous pharmacological characteristics and effec-
tiveness at least non-inferior to well-managed warfarin chan-
ged strategies of stroke prevention in AF hemorrhagic
complications, particularly life-threatening as ICH, is signifi-
cantly lower with NOACs, and reversal of anticoagulant effect
is not necessary in majority of bleeds. The use of PCC seems to
be reasonable in all cases where specific reversal agents are
not available. Idarucizumab is the first specific approved rever-
sal agent for dabigatran. Andexanet α and ciraparantag are
expected to complement strategies for bleeding management
in the next future. Bleeding itself, prothrombotic effect of
nonspecific reversal agents (e.g. PCC), or temporary interrup-
tion of anticoagulation, may be associated with transient
increase in risk of thromboembolism. Therefore, OAC should
be restarted as soon as possible to prevent this.
8. Expert commentary
For most of AF patients, except those with low stroke risk, the
net clinical benefit of OAC is in favor thromboembolism pre-
vention, even in presence of a high bleeding risk. As general
principle, it is always better to prevent a bleeding than to treat
it, therefore bleeding risk assessment should be a mandatory
component of management of patient under OAC. Thus, the
presence of risk factors for bleeding, especially those modifi-
able, should be always carefully evaluated. The HAS-BLED
bleeding score is a useful tool for this.
The landscape of stroke prevention has changed signifi-
cantly over past years with a growing use of NOACs in AF.
Nonetheless, lack of routinely available coagulation assays to
quantitatively assess anticoagulation effect of NOACs and
drug-specific reversal agents lead to under prescription of
NOACs in AF patients and/or overutilization of reduced
doses of NOAC in patients eligible for full dose.
General measures including mechanical compression or
surgical hemostasis, volume substitution, and hemodynamic
support are effective to treat most of bleeding episodes, and
when an elective surgical intervention is required, the tempor-
ary interruption of OAC with NOACs is easy and does not
require bridging therapy with low-molecular-weight heparin.
When bleeding is associated with hemodynamic instability
or is life-threatening because of bleeding site (e.g. ICH), non-
specific reversal agents such as PCC are necessary to achieve
hemostasis. Fresh frozen plasma may be also needed to man-
age coagulopathy.
Conventional coagulation tests were shown to be related to
NOAC concentration, but they offer only approximate assess-
ment of drug elimination or reversal. In life-threatening bleeding,
it deems inappropriate to delay treatment with reversal agents in
order to get confirmation of therapeutic level of anticoagulation.
Any interruptions in chronic OAC result in increased risk of
stroke or systemic embolism, which is even higher in case of
intentional reversal of anticoagulation effect with the NOAC.
Specific reversal agents have to be used as a first-line therapy
given absence of intrinsic prothrombotic effect that is attrib-
uted to nonspecific reversal agents, particularly recombinant
factor VIIa. Resumption of OAC after bleeding is challenging
with limited evidence derived from observational nonrando-
mized studies available to guide this; however, available data
is in favor of OAC. Labeling for the idarucizumab, the only
antidote approved so far, recommends to restart OAC as soon
as medically appropriate based on clinical judgment. Patients
education, shared decision-making, as well as values and pre-
ferences should be considered.
9. Five-year view
The use of NOACs for stroke prevention is increasing in non-
valvular AF. Although specific reversal agents would be used in
a minority of AF patients, their availability will make clinicians
more confident with respect to administration of NOACs, redu-
cing the inappropriate prescription of low-dose NOAC.
Idarucizumab is the only approved specific reversal agent;
it has been approved by the FDA with an accelerated approval
program because of unmet medical need, that is, reliable,
effective, and safe drug-specific reversal agent for dabigatran.
One acknowledged limitation of such path is adoption of
surrogate or intermediate clinical endpoints, which are
thought to translate into clinical benefit for patients.
Andexanet α was designated by the FDA as an orphan drug
and as a breakthrough therapy and was on accelerated
approval pathway, but industry was asked to provide addi-
tional data, and approval was delayed. Ciraparantag was
granted fast track designation from the FDA while phase 2
study with ciraparantag was ongoing.
Key issues
● Specific reversal agents, idarucizumab for dabigatran, andex-
anet α for apixaban, rivaroxaban, and edoxaban, and universal
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antidote ciraparantag will significantly improve the manage-
ment of life-threating bleedings in patients receiving a NOAC.
● Major or life-threatening hemorrhagic complications of OAC
are not common, and the NOACs were showed to be
advantageous compared to well-managed warfarin with
this respect, particularly for reduction of ICH.
● Pharmacological properties of all the NOACs allow relatively
rapid decrease in anticoagulant effect, therefore in vast
majority of hemorrhages, general supportive hemostatic
procedures will be sufficient for the resolution of bleeding.
● In life-threatening bleeding or urgent surgery, the availabil-
ity of specific reversal agents will facilitate the restoration of
safe hemostasis without prothrombotic side effects
observed in some cases with non-specific reversal agents.
● The availability of specific reversal agents would probably
improve the confidence of clinicians in the prescription of
NOACs, thus reducing the risk of inappropriate use of low-
doses of NOACs.
● Resumption of OAC after a safe hemostasis is reached,
should be considered to avoid thrombotic event.
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